Lv4
770 积分 2023-01-14 加入
Tolerance in the Age of Immunotherapy
2天前
已完结
EP08.02-029 Sunvozertinib in NSCLC Patients with EGFR Exon20 Insertion Mutations: Effect of Prior Treatment
4个月前
已完结
The changing treatment landscape of EGFR-mutant non-small-cell lung cancer
5个月前
已完结
BL-B01D1, a first-in-class EGFR–HER3 bispecific antibody–drug conjugate, in patients with locally advanced or metastatic solid tumours: a first-in-human, open-label, multicentre, phase 1 study
5个月前
已完结
Sunvozertinib for patients in China with platinum-pretreated locally advanced or metastatic non-small-cell lung cancer and EGFR exon 20 insertion mutation (WU-KONG6): single-arm, open-label, multicentre, phase 2 trial
5个月前
已完结
Discovery of YK-029A, a novel mutant EGFR inhibitor targeting both T790 M and exon 20 insertion mutations, as a treatment for NSCLC
5个月前
已完结
A patent review of small molecular inhibitors targeting EGFR exon 20 insertion (Ex20ins) (2019-present)
5个月前
已完结
MA12.11 Vebreltinib Plus PLB1004 In EGFR-Mutated, NSCLC with MET Amplification or MET Overexpression Following EGFR-TKI
5个月前
已关闭
Unlocking the potential of antibody–drug conjugates for cancer therapy
5个月前
已完结
MA15.13 Furmonertinib as Adjuvant Therapy for Completely Resected Stage IA with High-Risk Factors and IB NSCLC Patients with EGFR Mutations
5个月前
已关闭
皖公网安备34019202002308
